This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Posey, J. T. Articles by Lokeshwar, V. B. Search for Related Content PubMed PubMed Citation Articles by Posey, J. T. Articles by Lokeshwar, V. B.

Evaluation of the Prognostic Potential of Hyaluronic Acid and Hyaluronidase (HYAL1) for Prostate Cancer¹

Departments of Urology [J. T. P., M. S. S., S. E., M. S., F. C., V. B. L.], Department of Epidemiology [R. C. D.], and Cell Biology and Anatomy [V. B. L.], University of Miami School of Medicine, Miami, Florida 33101

Despite the development of nomograms designed to evaluate the prognosis of a patient with prostate cancer (CaP), the information has been limited to prostate-specific antigen (PSA), clinical stage, Gleason score, and tumor volume estimates. To improve our ability to predict prognosis, information regarding the molecular properties of CaP is needed. Hyaluronic acid (HA) is a glycosaminoglycan that promotes tumor metastasis. Hyaluronidase (HAase) is an enzyme that degrades HA into angiogenic fragments. We recently showed that in CaP tissues, whereas HA is localized mostly in the tumor-associated stroma, HYAL1 type HAase is exclusively localized in CaP cells (Lokeshwar et al. J. Biol. Chem., 276: 11922–11932, 2001). We evaluated the prognostic potential of HA and HYAL1 in CaP by immunohistochemistry.

Archival CaP specimens were obtained from patients who underwent radical retropubic prostatectomy for clinically localized CaP. Group 1 (n = 25) included patients who showed biochemical recurrence (PSA >0.4 ng/ml; mean recurrence: 21.3 months). Group 2 included patients with no clinical or biochemical recurrence (n = 45; mean follow-up: 80.9 months). For HA and HYAL1 staining, a biotinylated HA-binding protein and an anti-HYAL1 antibody were used. The staining was evaluated on the basis of intensity (0 to 3+) and as dense or sparse (for HA staining only) and then grouped as low grade and high grade.

In CaP specimens, HYAL1 was exclusively expressed in tumor cells. Although the stroma was stained positive for HA, 40% of tumor cells also expressed HA. HA, HYAL1, and combined HA-HYAL1 staining predicted progression with 96%, 84%, and 88% sensitivity, 55.5%, 80%, and 84.4% specificity, and 70%, 81.4%, and 85.7% accuracy, respectively. In the univariate analysis, preoperative PSA, Gleason sum, stage, margin, seminal vesicle, extra-prostatic extension (EPE), HA, HYAL1, and HA-HYAL1 were significant in predicting progression (P < 0.05). However, in the multiple logistic regression analysis, only EPE [odds ratio (OR) = 33.483; P = 0.002), HYAL1 (OR = 12.42; P = 0.009), HA-HYAL1 (OR = 18.048; P = 0.0033), and margin (OR = 26.948; P = 0.006)] were significant. Thus, in this 5-year follow-up study, HYAL1, together with EPE and margin, was found to be an independent prognostic indicator.

This article has been cited by other articles:

				S. Ganesh, M. Gonzalez-Edick, D. Gibbons, M. Van Roey, and K. Jooss Intratumoral Coadministration of Hyaluronidase Enzyme and Oncolytic Adenoviruses Enhances Virus Potency in Metastatic Tumor Models Clin. Cancer Res., June 15, 2008; 14(12): 3933 - 3941. [Abstract] [Full Text] [PDF]

				I. Poola, J. Abraham, J. J. Marshalleck, Q. Yue, V. B. Lokeshwar, G. Bonney, and R. L. DeWitty Molecular Risk Assessment for Breast Cancer Development in Patients with Ductal Hyperplasias Clin. Cancer Res., February 15, 2008; 14(4): 1274 - 1280. [Abstract] [Full Text] [PDF]

				R. Golshani, L. Lopez, V. Estrella, M. Kramer, N. Iida, and V. B. Lokeshwar Hyaluronic Acid Synthase-1 Expression Regulates Bladder Cancer Growth, Invasion, and Angiogenesis through CD44 Cancer Res., January 15, 2008; 68(2): 483 - 491. [Abstract] [Full Text] [PDF]

				P. Karihtala, Y. Soini, P. Auvinen, R. Tammi, M. Tammi, and V.-M. Kosma Hyaluronan in Breast Cancer: Correlations With Nitric Oxide Synthases and Tyrosine Nitrosylation J. Histochem. Cytochem., December 1, 2007; 55(12): 1191 - 1198. [Abstract] [Full Text] [PDF]

				A. G. Bharadwaj, K. Rector, and M. A. Simpson Inducible Hyaluronan Production Reveals Differential Effects on Prostate Tumor Cell Growth and Tumor Angiogenesis J. Biol. Chem., July 13, 2007; 282(28): 20561 - 20572. [Abstract] [Full Text] [PDF]

				E. S.A. Hofinger, M. Spickenreither, J. Oschmann, G. Bernhardt, R. Rudolph, and A. Buschauer Recombinant human hyaluronidase Hyal-1: insect cells versus Escherichia coli as expression system and identification of low molecular weight inhibitors Glycobiology, April 1, 2007; 17(4): 444 - 453. [Abstract] [Full Text] [PDF]

				B. P Alter, P. S Rosenberg, and L. C Brody Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2 J. Med. Genet., January 1, 2007; 44(1): 1 - 9. [Abstract] [Full Text] [PDF]

				V. B. Lokeshwar, V. Estrella, L. Lopez, M. Kramer, P. Gomez, M. S. Soloway, and B. L. Lokeshwar HYAL1-v1, An Alternatively Spliced Variant of HYAL1 Hyaluronidase: A Negative Regulator of Bladder Cancer Cancer Res., December 1, 2006; 66(23): 11219 - 11227. [Abstract] [Full Text] [PDF]

				J. L. Kovar, M. A. Johnson, W. M. Volcheck, J. Chen, and M. A. Simpson Hyaluronidase Expression Induces Prostate Tumor Metastasis in an Orthotopic Mouse Model Am. J. Pathol., October 1, 2006; 169(4): 1415 - 1426. [Abstract] [Full Text] [PDF]

				M. A. Simpson Concurrent Expression of Hyaluronan Biosynthetic and Processing Enzymes Promotes Growth and Vascularization of Prostate Tumors in Mice Am. J. Pathol., July 1, 2006; 169(1): 247 - 257. [Abstract] [Full Text] [PDF]

				T. Isoyama, D. Thwaites, M. G. Selzer, R. I. Carey, R. Barbucci, and V. B. Lokeshwar Differential selectivity of hyaluronidase inhibitors toward acidic and basic hyaluronidases Glycobiology, January 1, 2006; 16(1): 11 - 21. [Abstract] [Full Text] [PDF]

				V. B. Lokeshwar, W. H. Cerwinka, T. Isoyama, and B. L. Lokeshwar HYAL1 Hyaluronidase in Prostate Cancer: A Tumor Promoter and Suppressor Cancer Res., September 1, 2005; 65(17): 7782 - 7789. [Abstract] [Full Text] [PDF]

				J. Chen, X.-M. Xu, C. B. Underhill, S. Yang, L. Wang, Y. Chen, S. Hong, K. Creswell, and L. Zhang Tachyplesin Activates the Classic Complement Pathway to Kill Tumor Cells Cancer Res., June 1, 2005; 65(11): 4614 - 4622. [Abstract] [Full Text] [PDF]

				V. B. Lokeshwar, W. H. Cerwinka, and B. L. Lokeshwar HYAL1 Hyaluronidase: A Molecular Determinant of Bladder Tumor Growth and Invasion Cancer Res., March 15, 2005; 65(6): 2243 - 2250. [Abstract] [Full Text] [PDF]

				D M Peehl Primary cell cultures as models of prostate cancer development Endocr. Relat. Cancer, March 1, 2005; 12(1): 19 - 47. [Abstract] [Full Text] [PDF]